{"product_id":"alks-bcg-matrix","title":"(ALKS) Alkermes plc BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Alkermes plc BCG Matrix helps you see how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio analysis. The content on this page is a real preview of the actual report, so you can review the format and sample insights before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLYBALVI schizophrenia 2021\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLYBALVI was approved in 2021 for schizophrenia in adults, and it combines olanzapine with samidorphan in one oral dose. In Alkermes plc’s BCG view, it is still a Star in an early growth phase, not yet a mature cash engine like older CNS brands. Its role is to expand share in a large, long-treated schizophrenia market while the portfolio shifts beyond legacy products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLYBALVI bipolar I disorder 2021\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eApproved in 2021 for bipolar I disorder in adults, LYBALVI added a second commercial indication to Alkermes plc's oral franchise. That wider label gives the product a larger growth runway than a single-indication launch, and Alkermes plc still markets it alongside schizophrenia. In BCG terms, the mix of expansion potential and repeat prescribing supports a Stars profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVUMERITY relapsing MS 2019\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVUMERITY, approved in 2019, is Alkermes plc’s oral diroximel fumarate for relapsing forms of multiple sclerosis. The Stars case fits a large, still-active market: about 1 million people in the U.S. live with MS, and roughly 85% are diagnosed first with relapsing disease. Oral dosing helps keep it relevant against injectables and infusions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eARISTADA schizophrenia 2015\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eARISTADA, approved in 2015 for adult schizophrenia, fits Alkermes plc’s Stars bucket because it is a long-acting injectable aripiprazole franchise with durable repeat dosing. Its monthly and extended-interval use helps keep patients in LAI care pathways, where persistence is often stronger than with daily oral therapy. In Alkermes plc’s 2025-2026 mix, ARISTADA remains a key branded asset tied to ongoing refill-based revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2015 approval for adult schizophrenia\u003c\/li\u003e\n\u003cli\u003eLong-acting injectable aripiprazole\u003c\/li\u003e\n\u003cli\u003eRepeat dosing supports retention\u003c\/li\u003e\n\u003cli\u003eLAI pathway adoption drives stickiness\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eARISTADA INITIO start regimen 2021\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eARISTADA INITIO is the starter regimen for ARISTADA, helping patients begin long-acting aripiprazole treatment in one day and supporting faster franchise uptake. In Alkermes plc's injectable antipsychotic platform, it fits the \"Star\" profile because it drives access and switch rates into a growing LAI market, which reached roughly $7 billion globally in 2025. Its value is tied to ARISTADA's broader prescription base and recurring treatment flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne-day start supports faster initiation\u003c\/li\u003e\n\u003cli\u003eTied to ARISTADA franchise growth\u003c\/li\u003e\n\u003cli\u003eBacks Alkermes plc LAI expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlkermes’ Star Products: LYBALVI, ARISTADA, and VUMERITY Drive Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlkermes plc’s Stars are the products with the clearest growth and repeat-use pull: LYBALVI, ARISTADA, ARISTADA INITIO, and VUMERITY. LYBALVI had 2025 net sales of about $420 million, while ARISTADA generated about $541 million and VUMERITY about $294 million, showing the scale behind the franchise. ARISTADA INITIO supports faster LAI starts and helps convert new patients into recurring use. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025 value\u003c\/th\u003e\n\u003cth\u003eStar driver\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLYBALVI\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003ctd\u003eTwo-indication growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eARISTADA\u003c\/td\u003e\n\u003ctd\u003e$541M\u003c\/td\u003e\n\u003ctd\u003eRepeat LAI dosing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVUMERITY\u003c\/td\u003e\n\u003ctd\u003e$294M\u003c\/td\u003e\n\u003ctd\u003eOral MS demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAlkermes plc BCG Matrix maps its portfolio to spot Stars, Cash Cows, Question Marks, and Dogs for invest\/hold\/divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page Alkermes plc BCG Matrix that quickly spots pain points and priority moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear source trail for Alkermes plc, strengthening credibility and helping decision-makers verify key assumptions fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVIVITROL alcohol dependence 2006\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVIVITROL, approved in 2006 for alcohol dependence, is one of Alkermes plc’s longest-running marketed brands. Its once-monthly 380 mg injection and long prescribing history support steady repeat use. In FY2025, this mature franchise helped Alkermes plc generate recurring cash flow from an established patient base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVIVITROL opioid dependence relapse prevention 2006\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVIVITROL, approved in 2006 for relapse prevention after opioid detoxification, gives Alkermes plc a second use for the same monthly injectable brand. That dual-label setup helps keep demand steady and low growth, which fits a Cash Cow in the BCG Matrix. In 2025, it still supported recurring branded revenue and cash flow from one product family.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRISPERDAL CONSTA Janssen royalty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRISPERDAL CONSTA is a long-established long-acting risperidone franchise, so Alkermes plc earns collaboration economics from a mature, low-growth market. That makes it a classic Cash Cow: steady royalties, modest reinvestment needs, and limited upside tied to new patient growth. The asset still helps fund Alkermes plc’s higher-growth pipeline and commercial spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eINVEGA SUSTENNA paliperidone LAI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eINVEGA SUSTENNA is a mature monthly paliperidone LAI and a clear Cash Cow for Alkermes plc through Janssen collaboration economics. Janssen reported global INVEGA SUSTENNA sales of about $4.1 billion in 2025, while growth stayed modest versus newer schizophrenia launches, so the brand remains large but slow-moving.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge, steady schizophrenia franchise\u003c\/li\u003e\n\u003cli\u003eMonthly LAI supports repeat use\u003c\/li\u003e\n\u003cli\u003eAlkermes earns collaboration economics\u003c\/li\u003e\n\u003cli\u003eGrowth is slower than new products\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eXEPLION INVEGA TRINZA TREVICTA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXEPLION, INVEGA TRINZA, and TREVICTA are extended-interval paliperidone palmitate LAIs with mature schizophrenia demand, so they fit Cash Cows: high share in a steady market, low growth, and reliable cash generation. TREVICTA is the 3-month version, while INVEGA TRINZA and XEPLION anchor long-acting maintenance use. For Alkermes plc analysis, their value is the cash they can throw off, not expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstablished LAI schizophrenia brands\u003c\/li\u003e\n\u003cli\u003eStable, mature demand profile\u003c\/li\u003e\n\u003cli\u003eCash generation over growth\u003c\/li\u003e\n\u003cli\u003eLow incremental investment need\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlkermes’ Mature Brands Keep Cash Flowing in FY2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn FY2025, Alkermes plc's Cash Cows were its mature LAI and branded franchises, led by VIVITROL and collaboration assets tied to RISPERDAL CONSTA, INVEGA SUSTENNA, INVEGA TRINZA, XEPLION, and TREVICTA. These products sit in slow-growth markets, but they still generate recurring cash with limited reinvestment needs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVIVITROL\u003c\/td\u003e\n\u003ctd\u003eMonthly, mature cash flow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eINVEGA SUSTENNA\u003c\/td\u003e\n\u003ctd\u003eJanssen sales about $4.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eAlkermes plc Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Alkermes plc BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No watermarks, no demo pages—just the full, ready-to-use report. It’s formatted for clear strategic analysis and professional presentation. Once purchased, the file is available for immediate download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALKS 5461 0 approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALKS 5461 was an adjunct treatment candidate for major depressive disorder, but it received no approval and Alkermes plc later discontinued the program after regulatory setbacks. The asset generated no commercial product sales, so it fits the Dogs quadrant in the Alkermes plc BCG Matrix. That means it consumed R\u0026amp;D capital without creating revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy terminated CNS programs 0 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy terminated CNS programs generated 0 sales in fiscal 2025 and sit in Alkermes plc’s dog bucket. These older neuroscience candidates never reached approval, so they still reflect historic R and D spend but no current cash flow. With low share and no market access, they add cost, not growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscontinued preclinical assets 0 market share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlkermes plc's discontinued preclinical assets stayed at 0 market share and never crossed the commercialization threshold. They produced no branded product line and no sales base, so they added no direct revenue in 2025. As of end-2025, their strategic value was minimal versus Alkermes plc's $1.4 billion FY2025 revenue base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-core historical pipeline 0 growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlkermes plc’s non-core historical pipeline is a clear Dog: older internal programs have been de-prioritized, carry no visible market share, and show 0% growth. In FY2025, Alkermes generated $1.5 billion in total revenue, so these legacy assets were immaterial versus core products. Capital is better kept out of these programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOlder programs, no priority\u003c\/li\u003e\n\u003cli\u003eNo visible market share\u003c\/li\u003e\n\u003cli\u003eGrowth outlook: 0%\u003c\/li\u003e\n\u003cli\u003eDo not fund further\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHistorical write-off programs 0 cash generation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlkermes plc's historical write-off programs are legacy assets that were exited or fully impaired, so they generate 0 cash for current operations. That matches the BCG \"dog\" profile: low share, no growth, and no reinvestment payoff. They drain attention, but not because they still create value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLegacy programs: written down or exited\u003c\/li\u003e\n\u003cli\u003eCurrent cash generation: 0\u003c\/li\u003e\n\u003cli\u003eBCG fit: low-growth, low-share dog\u003c\/li\u003e\n\u003cli\u003eValue today: none to operating cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlkermes’ Legacy CNS Dogs: Zero Sales, Zero Share, Zero Payoff\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlkermes plc’s Dogs are the discontinued legacy CNS programs: they generated 0 sales in FY2025, held no market share, and added no current cash flow. They fit the low-share, no-growth BCG dog bucket, so further funding has no clear payoff versus Alkermes plc’s $1.5 billion FY2025 revenue base.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDog assets sales\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket share\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlkermes plc revenue\u003c\/td\u003e\n\u003ctd\u003e$1.5 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNemvaleukin alfa mucosal melanoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNemvaleukin alfa, an engineered IL-2 pathway fusion protein, was advanced in oncology development as a Question Mark in Alkermes plc’s BCG matrix. Mucosal melanoma is rare, about 1% of melanomas, and has high unmet need, but clinical and regulatory outcomes remain uncertain despite early response signals in small studies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNemvaleukin alfa platinum-resistant ovarian cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNemvaleukin alfa in platinum-resistant ovarian cancer is another late-stage oncology bet for Alkermes plc, but this market is hard to crack. About 70% of ovarian cancers are found at advanced stage, and platinum resistance affects roughly 20%-30% of patients after first-line treatment. The asset needs strong Phase 2\/3 data to turn this question mark into real commercial value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALKS 2680 narcolepsy type 1\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALKS 2680 is a Question Mark in Alkermes plc's BCG Matrix: an oral orexin 2 receptor agonist in development for narcolepsy type 1, a rare sleep disorder with an estimated prevalence of about 25 to 50 per 100,000 people. The market is growing, the unmet need is clear, and the asset still has no sales. If clinical data land well, it could move toward a future Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eALKS 2680 narcolepsy type 2\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eALKS 2680 also targets narcolepsy type 2, so Alkermes plc could address a larger patient pool than narcolepsy type 1 alone. U.S. narcolepsy affects about 1 in 2,000 people, and type 2 is often the larger share of cases, but ALKS 2680 still has 0% market share because it is not approved.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroader market than one diagnosis\u003c\/li\u003e\n\u003cli\u003eType 2 expands patient reach\u003c\/li\u003e\n\u003cli\u003eCurrent share remains zero\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eALKS 2680 idiopathic hypersomnia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eALKS 2680 targets idiopathic hypersomnia, a sleep disorder that affects an estimated 37 to 50 people per 100,000 adults, so the unmet need is real. But Alkermes plc has no commercial sales here yet, making it a classic high-potential, low-share question mark.\u003c\/p\u003e\n\u003cp\u003eThe asset is still pre-launch and the market is unproven, so near-term value depends on clinical data, dosing, and payer uptake. For Alkermes plc, that means upside can be large, but cash generation is still zero.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eHigh unmet need, limited treatment options\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003ePre-commercial, no revenue yet\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003ePotential orexin-based growth optionality\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlkermes’ High-Upside Bets: Big Potential, No Sales Yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlkermes plc’s Question Marks are still early, high-upside bets with no sales yet. Nemvaleukin alfa and ALKS 2680 both target large unmet-need niches, but value now depends on late-stage data, approval risk, and payer adoption. ALKS 2680 also keeps broader upside through narcolepsy type 2 and idiopathic hypersomnia.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eKey point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNemvaleukin alfa\u003c\/td\u003e\n\u003ctd\u003eClinical\u003c\/td\u003e\n\u003ctd\u003eNo revenue; oncology risk high\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eALKS 2680\u003c\/td\u003e\n\u003ctd\u003ePre-launch\u003c\/td\u003e\n\u003ctd\u003e0% share; broader sleep upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57233999593737,"sku":"alks-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/alks-bcg-matrix.webp?v=1785710282","url":"https:\/\/dcfanalyst.com\/products\/alks-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}